Skip to main content

Advertisement

SpringerLink
Log in

Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Hereditary transthyretin (ATTR) amyloidosis is a life-threatening, autosomal dominant, systemic amyloidosis caused by mutant transthyretin. In addition to ATTRV30M in endemic and non-endemic areas, more than 140 non-V30M mutations occur worldwide. The aim of this study was to analyze the clinical characteristics and genetic frequencies of hereditary ATTR amyloidosis. Diagnostic results and clinical manifestations of hereditary ATTR amyloidosis from April 1, 2012, to March 31, 2017, at Amyloidosis Medical Practice Center, Kumamoto University Hospital were analyzed. One hundred and four patients received a diagnosis of symptomatic hereditary ATTR amyloidosis. The following mutations of the TTR gene and their percentages were found: V30M in endemic areas, 10.6%; V30M in non-endemic areas, 51.0%; and non-V30M, 38.5%. The ages at onset of patients with ATTRV30M amyloidosis in non-endemic areas (66.6 ± 8.7 years) and those with non-V30M ATTR amyloidosis (55.8 ± 13.6 years) were significantly higher than those with ATTRV30M amyloidosis in endemic areas (37.0 ± 12.6 years). Of patients with ATTRV30M amyloidosis in endemic and non-endemic areas, and non-V30M ATTR amyloidosis, 63.6, 66.0, and 27.5% initially presented with polyneuropathy, respectively. Of patients with ATTRV30M amyloidosis in endemic areas, 81.8% had a family history of this disease. However, a significantly smaller percentage of patients with ATTRV30M amyloidosis (30.0%) in non-endemic areas and non-V30M ATTR amyloidosis (34.0%) had a family history. Patients with ATTRV30M amyloidosis in non-endemic areas and patients with non-V30M ATTR amyloidosis occurred more frequently than previously believed, and their clinical manifestations were diverse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23(4):209–213

    Article  CAS  PubMed  Google Scholar 

  2. Kerschen P, Planté-Bordeneuve V (2016) Current and future treatment approaches in transthyretin familial amyloid polyneuropathy. Curr Treat Options Neurol 18(12):53

    Article  PubMed  Google Scholar 

  3. Ando Y, Nakamura M, Araki S (2005) Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 62(7):1057–1062

    Article  PubMed  Google Scholar 

  4. Araki S (1984) Type I familial amyloidotic polyneuropathy (Japanese type). Brain Dev 6(2):128–133

    Article  CAS  PubMed  Google Scholar 

  5. Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75(3):408–427

    Article  CAS  PubMed  Google Scholar 

  6. Andersson R (1976) Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 590:1–64

    CAS  PubMed  Google Scholar 

  7. Adams D, Cauquil C, Labeyrie C (2017) Familial amyloid polyneuropathy. Curr Opin Neurol 30(5):481–489

    Article  CAS  PubMed  Google Scholar 

  8. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD (2005) A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 12(2):127–130

    Article  CAS  PubMed  Google Scholar 

  9. Yamashita T, Ando Y, Ueda M, Nakamura M, Okamoto S, Zeledon ME, Hirahara T, Hirai T, Ueda A, Misumi Y, Obayashi K, Inomata H, Uchino M (2008) Effect of liver transplantation on transthyretin Tyr114Cys-related cerebral amyloid angiopathy. Neurology 70(2):123–128

    Article  CAS  PubMed  Google Scholar 

  10. Planté-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, Azoulay D, Feray C, Damy T, Lefaucheur JP (2017) Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol 264(2):268–276

    Article  PubMed  Google Scholar 

  11. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, Adams D (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109

    Article  PubMed  PubMed Central  Google Scholar 

  12. Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D (2016) Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263(5):916–924

    Article  CAS  PubMed  Google Scholar 

  13. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260(11):2802–2814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369(9):819–829

    Article  CAS  PubMed  Google Scholar 

  15. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310(24):2658–2667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M (2012) Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 78(9):637–643

    Article  CAS  PubMed  Google Scholar 

  18. Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5–9

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y (2009) SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 55(6):1223–1227

    Article  CAS  PubMed  Google Scholar 

  20. Ando Y, Ohlsson PI, Suhr O, Nyhlin N, Yamashita T, Holmgren G, Danielsson A, Sandgren O, Uchino M, Ando M (1996) A new simple and rapid screening method for variant transthyretin-related amyloidosis. Biochem Biophys Res Commun 228(2):480–483

    Article  CAS  PubMed  Google Scholar 

  21. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G, Study Group for Hereditary Neuropathy in Japan (2002) Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59(11):1771–1776

    Article  PubMed  Google Scholar 

  22. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63(1):129–138

    Article  CAS  PubMed  Google Scholar 

  23. Ki Misu, Hattori N, Nagamatsu M, Si Ikeda, Ando Y, Nakazato M, Yi Takei, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G (1999) Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 122(10):1951–1962

    Article  Google Scholar 

  24. Yamashita T, Ueda M, Saga N, Nanto K, Tasaki M, Masuda T, Misumi Y, Oda S, Fujimoto A, Amano T, Takamatsu K, Yamashita S, Obayashi K, Matsui H, Ando Y (2016) Hereditary amyloidosis with cardiomyopathy caused by the novel variant transthyretin A36D. Amyloid 23(3):207–208

    Article  PubMed  Google Scholar 

  25. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G (2011) Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 18(2):53–62

    Article  CAS  PubMed  Google Scholar 

  26. Planté-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, Said G (1998) Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 51(3):708–714

    Article  PubMed  Google Scholar 

  27. Conceição I, De Carvalho M (2007) Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35(1):116–118

    Article  PubMed  Google Scholar 

  28. Okumura K, Yamashita T, Masuda T, Misumi Y, Ueda A, Ueda M, Obayashi K, Jono H, Yamashita S, Inomata Y, Ando Y (2016) Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation. Amyloid 23(1):39–45

    Article  CAS  PubMed  Google Scholar 

  29. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31

    Article  PubMed  PubMed Central  Google Scholar 

  30. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB (2009) Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl 15(10):1229–1235

    Article  PubMed  Google Scholar 

  31. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341(8853):1113–1116

    Article  CAS  PubMed  Google Scholar 

  32. Gustavsson A, Jahr H, Tobiassen R, Jacobson DR, Sletten K, Westermark P (1995) Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Investig 73(5):703–708

    CAS  PubMed  Google Scholar 

  33. Westermark P, Sletten K, Johansson B, Cornwell GG 3rd (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87(7):2843–2845

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ando Y, Tanaka Y, Ando E, Yamashita T, Nishida Y, Tashima K, Suga M, Uchino M, Ando M (1995) Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet 345(8943):195–196

    Article  CAS  PubMed  Google Scholar 

  35. Suhr OB, Larsson M, Ericzon BG, Wilczek HE, FAPWTRʼs investigators (2016) Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry. Transplantation 100(2):373–381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121(1):73–85

    Article  CAS  PubMed  Google Scholar 

  37. Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, Ikeda S, Lavatelli F, Obici L, Quarta CC, Leone O, Jono H, Ueda M, Lorenzini M, Liepnieks J, Ohshima T, Tasaki M, Yamashita T, Westermark P (2013) Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 20(3):142–150

    Article  CAS  PubMed  Google Scholar 

  38. Rajabally YA, Adams D, Latour P, Attarian S (2016) Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses. J Neurol Neurosurg Psychiatry 87(10):1051–1060

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan

    Taro Yamashita, Mitsuharu Ueda, Yohei Misumi, Teruaki Masuda, Toshiya Nomura, Masayoshi Tasaki, Kotaro Takamatsu & Yukio Ando

  2. Amyloidosis Medical Practice Center, Kumamoto University Hospital, Kumamoto, Japan

    Taro Yamashita

  3. Department of Morphological and Physiological Sciences, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Masayoshi Tasaki & Konen Obayashi

  4. Division of Genetic Diagnosis, Department of Laboratory Medicine, Kumamoto University Hospital, Kumamoto, Japan

    Keiko Sasada

  5. Department of Molecular Laboratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Hirotaka Matsui

Authors
  1. Taro Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuharu Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yohei Misumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruaki Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiya Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayoshi Tasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kotaro Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keiko Sasada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Konen Obayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hirotaka Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yukio Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taro Yamashita.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical standards

This Institutional Review Board of the Graduate School of Medical Sciences, Kumamoto University (No. 1172, 1387) approved this study.

Informed consent

All patients gave their informed consent prior to their inclusion in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamashita, T., Ueda, M., Misumi, Y. et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol 265, 134–140 (2018). https://doi.org/10.1007/s00415-017-8640-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-017-8640-7

Keywords

Search

Navigation